首页 > 最新文献

Optometry and Vision Science最新文献

英文 中文
Running the enrollment numbers on ophthalmic clinical trials in the United States. 统计美国眼科临床试验的注册人数。
IF 1.4 4区 医学 Q3 OPHTHALMOLOGY Pub Date : 2024-09-03 DOI: 10.1097/opx.0000000000002174
Andrew D Pucker,Nicole Derthick,Lanita Scott
SIGNIFICANCEThis is one of the first reports to summarize the enrollment metrics for ophthalmology trials completed in the United States (US).PURPOSEThis study aimed to describe US ophthalmology clinical trial enrollment metrics to facilitate planning and budgeting of US Food and Drug Administration-regulated ophthalmological drugs trials.METHODSA GlobalData PLC search was conducted on or before February 27, 2024, to evaluate the clinical trial landscape for completed ophthalmology clinical trials conducted in the US. The primary search contained only the term "ophthalmology," which was restricted to trials that were completed and were conducted within the US. Trials were classified as multicenter when trials included three sites or more, and when the enrollment search resulted in ≥30 multicenter trials for an individual indication, enrollment data were further broken down by Food and Drug Administration trial phase.RESULTThe search yielded 2229 trials, which analyzed 980 different drugs produced by 854 different sponsors. The most common indications evaluated in US trials were macular degeneration, glaucoma, macular edema, allergies, and keratoconjunctivitis. Multicenter trials by indication had an overall median enrollment period range of 4.8 to 35.1 months; number of subjects enrollment, range of 36 to 518 subjects; number of sites utilized, range of 4 to 74 sites; and enrollment rate, range of 0.11 to 4.04 subjects/sites per month. There were 17 indications with ≥30 multicenter trials, which allowed for enrollment metric calculation by trial phase.CONCLUSIONSThis study provides sponsors with an understanding of the number of subjects and sites needed to complete a trial while also setting realistic enrollment timelines. Although this work represents the US market, more work is needed to better understand other countries given that country-specific guidelines and subject beliefs may impact enrollment metrics.
本研究旨在描述美国眼科临床试验的入组指标,以促进美国食品药品管理局监管的眼科药物试验的规划和预算编制。方法在 2024 年 2 月 27 日或之前对 GlobalData PLC 进行了搜索,以评估在美国进行的已完成眼科临床试验的临床试验情况。主要搜索只包含 "眼科 "一词,仅限于在美国境内完成并进行的试验。当试验包括三个或三个以上的试验点时,试验被归类为多中心试验;当注册检索结果显示针对单个适应症的多中心试验≥30 项时,注册数据将按食品与药物管理局的试验阶段进一步细分。结果检索结果显示有 2229 项试验,分析了 854 个不同赞助商生产的 980 种不同药物。美国试验中最常见的适应症是黄斑变性、青光眼、黄斑水肿、过敏和角结膜炎。按适应症划分的多中心试验的总体中位注册期从4.8个月到35.1个月不等;注册受试者人数从36人到518人不等;使用的研究机构从4个到74个不等;注册率从每月0.11人到4.04人/研究机构不等。有 17 个适应症的多中心试验≥30 例,因此可以按试验阶段计算入组指标。虽然这项工作代表的是美国市场,但鉴于各国的指导方针和受试者的想法可能会影响入组指标,因此还需要做更多的工作来更好地了解其他国家。
{"title":"Running the enrollment numbers on ophthalmic clinical trials in the United States.","authors":"Andrew D Pucker,Nicole Derthick,Lanita Scott","doi":"10.1097/opx.0000000000002174","DOIUrl":"https://doi.org/10.1097/opx.0000000000002174","url":null,"abstract":"SIGNIFICANCEThis is one of the first reports to summarize the enrollment metrics for ophthalmology trials completed in the United States (US).PURPOSEThis study aimed to describe US ophthalmology clinical trial enrollment metrics to facilitate planning and budgeting of US Food and Drug Administration-regulated ophthalmological drugs trials.METHODSA GlobalData PLC search was conducted on or before February 27, 2024, to evaluate the clinical trial landscape for completed ophthalmology clinical trials conducted in the US. The primary search contained only the term \"ophthalmology,\" which was restricted to trials that were completed and were conducted within the US. Trials were classified as multicenter when trials included three sites or more, and when the enrollment search resulted in ≥30 multicenter trials for an individual indication, enrollment data were further broken down by Food and Drug Administration trial phase.RESULTThe search yielded 2229 trials, which analyzed 980 different drugs produced by 854 different sponsors. The most common indications evaluated in US trials were macular degeneration, glaucoma, macular edema, allergies, and keratoconjunctivitis. Multicenter trials by indication had an overall median enrollment period range of 4.8 to 35.1 months; number of subjects enrollment, range of 36 to 518 subjects; number of sites utilized, range of 4 to 74 sites; and enrollment rate, range of 0.11 to 4.04 subjects/sites per month. There were 17 indications with ≥30 multicenter trials, which allowed for enrollment metric calculation by trial phase.CONCLUSIONSThis study provides sponsors with an understanding of the number of subjects and sites needed to complete a trial while also setting realistic enrollment timelines. Although this work represents the US market, more work is needed to better understand other countries given that country-specific guidelines and subject beliefs may impact enrollment metrics.","PeriodicalId":19649,"journal":{"name":"Optometry and Vision Science","volume":"8 1","pages":"523-529"},"PeriodicalIF":1.4,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142203441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of age and race on axial elongation in myopic children: A systematic review and meta-regression. 年龄和种族对近视儿童轴伸长的影响:系统回顾与元回归。
IF 1.4 4区 医学 Q3 OPHTHALMOLOGY Pub Date : 2024-09-03 DOI: 10.1097/opx.0000000000002176
Noel A Brennan,Wright Shamp,Elizabeth Maynes,Xu Cheng,Mark A Bullimore
PURPOSEAxial elongation is the basis of progression in primary myopia and the preferred metric to monitor its evolution. We conducted a meta-regression to model axial elongation and its associated factors in children with low to moderate myopia.METHODSA comprehensive electronic systematic search was performed using Ovid Medline, EMBASE, and Cochrane Central Register of Controlled Trials of studies conducted up until October 2021. The mean rate of axial elongation was analyzed using a multivariate linear mixed-effects meta-regression model, with backward stepwise elimination of nonsignificant covariates. The model included three levels of random effects, allowing both prediction and confidence intervals to be estimated.RESULTSA total of 64 studies with 83 subpopulations and 142 evaluations of mean axial change from baseline met our inclusion criteria and had no missing significant covariates in the final model. A separate analysis including all populations with axial length data (202 evaluations) but missing variance or covariate data produced a similar model to that for the analysis with complete data. The mean axial elongation is 38% greater in Asian children (95% confidence interval, 19 to 61%; p<0.01) compared with non-Asians, but both groups show a 15% decline per year as age increases (95% confidence interval, 12 to 17% p<0.0001). Prediction intervals indicate substantial variability around the axial elongation estimates.CONCLUSIONSThis analysis provides mean values of axial elongation for evaluation of efficacy of myopia control. The broad prediction intervals emphasize the large range of individual axial elongation rates in the population, illustrating the challenge in managing individual children. Interpretation of the analysis is limited by the use of aggregated data rather than individual subject data.
目的轴伸长是原发性近视发展的基础,也是监测其演变的首选指标。我们对中低度近视儿童的轴伸长及其相关因素进行了元回归建模。方法使用 Ovid Medline、EMBASE 和 Cochrane Central Register of Controlled Trials 对截至 2021 年 10 月的研究进行了全面的电子系统检索。采用多变量线性混合效应元回归模型对平均轴伸长率进行分析,并向后逐步剔除不显著的协变量。结果共有 64 项研究、83 个亚人群和 142 次对平均轴向基线变化的评估符合我们的纳入标准,并且在最终模型中没有缺失的重要协变量。一项单独的分析包括了所有有轴向长度数据(202 次评估)但缺失方差或协变量数据的人群,该分析得出的模型与完整数据分析得出的模型相似。与非亚洲人相比,亚洲儿童的平均轴向伸长率高出38%(95%置信区间,19%至61%;P<0.01),但随着年龄的增长,两组儿童的平均轴向伸长率每年均下降15%(95%置信区间,12%至17%;P<0.0001)。预测区间表明,轴向伸长率估计值周围存在很大的变异性。结论这项分析提供了轴向伸长率的平均值,用于评估近视控制的效果。广泛的预测区间强调了人群中个体轴向伸长率的巨大范围,说明了管理个体儿童所面临的挑战。由于使用的是综合数据而非个体数据,因此对分析结果的解释受到了限制。
{"title":"Influence of age and race on axial elongation in myopic children: A systematic review and meta-regression.","authors":"Noel A Brennan,Wright Shamp,Elizabeth Maynes,Xu Cheng,Mark A Bullimore","doi":"10.1097/opx.0000000000002176","DOIUrl":"https://doi.org/10.1097/opx.0000000000002176","url":null,"abstract":"PURPOSEAxial elongation is the basis of progression in primary myopia and the preferred metric to monitor its evolution. We conducted a meta-regression to model axial elongation and its associated factors in children with low to moderate myopia.METHODSA comprehensive electronic systematic search was performed using Ovid Medline, EMBASE, and Cochrane Central Register of Controlled Trials of studies conducted up until October 2021. The mean rate of axial elongation was analyzed using a multivariate linear mixed-effects meta-regression model, with backward stepwise elimination of nonsignificant covariates. The model included three levels of random effects, allowing both prediction and confidence intervals to be estimated.RESULTSA total of 64 studies with 83 subpopulations and 142 evaluations of mean axial change from baseline met our inclusion criteria and had no missing significant covariates in the final model. A separate analysis including all populations with axial length data (202 evaluations) but missing variance or covariate data produced a similar model to that for the analysis with complete data. The mean axial elongation is 38% greater in Asian children (95% confidence interval, 19 to 61%; p<0.01) compared with non-Asians, but both groups show a 15% decline per year as age increases (95% confidence interval, 12 to 17% p<0.0001). Prediction intervals indicate substantial variability around the axial elongation estimates.CONCLUSIONSThis analysis provides mean values of axial elongation for evaluation of efficacy of myopia control. The broad prediction intervals emphasize the large range of individual axial elongation rates in the population, illustrating the challenge in managing individual children. Interpretation of the analysis is limited by the use of aggregated data rather than individual subject data.","PeriodicalId":19649,"journal":{"name":"Optometry and Vision Science","volume":"63 1","pages":"497-507"},"PeriodicalIF":1.4,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142226068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in corneal epithelial irregularity following treatment with artificial tears. 人工泪液治疗后角膜上皮不规则性的变化。
IF 1.6 4区 医学 Q3 OPHTHALMOLOGY Pub Date : 2024-09-01 Epub Date: 2024-05-23 DOI: 10.1097/OPX.0000000000002136
Jacqueline Tan, Ngozi Chidi-Egboka, Tianni Jia, Jared Showyin, Fiona Stapleton

Significance: Dry eye sufferers have a highly irregular corneal epithelial surface compared with those without dry eye. This study demonstrated that corneal epithelial thickness irregularity can be significantly reduced after as little as 48 hours following treatment with regular use of topical ocular lubricants.

Purpose: This study aimed to compare changes in corneal epithelial thickness irregularity factor (EIF) and ocular symptoms in a population with symptoms of dry eye before and up to 4 weeks after treatment with two commercially available lubricating eye drops versus saline.

Methods: We conducted a prospective single-center, investigator-masked, randomized, parallel-group dispensing study. Participants with moderate to severe symptoms of dry eye (Ocular Surface Disease Index score >23 at baseline) were enrolled and randomly assigned to receive either 0.15% hyaluronic acid + hydroxypropyl guar, 0.2% hyaluronic acid, or saline (16 in each group). Corneal epithelial thickness measurements were obtained along vertical and horizontal CASIA SS-1000 Optical Coherence Tomography scans at baseline and after 48 hours, 2 weeks, and 4 weeks. The Ocular Surface Disease Index questionnaire was administered at baseline, 2 weeks, and 4 weeks.

Results: Forty-eight participants (male-to-female ratio, 17:31) completed the study. Horizontal EIF was significantly lower at all follow-up visits compared with baseline (p=0.001), but there were no significant differences between study eye drops (p=0.34). No significant difference in vertical EIF was observed over time (p=0.32) or between eye drops (p=0.08). Ocular symptoms significantly improved after 2 and 4 weeks of treatment compared with baseline (p<0.001), but no differences were observed between eye drops (p=0.46).

Conclusions: All treatments were effective for reducing EIF along the horizontal meridian 48 hours after initiation of treatment, and improvements were maintained for 4 weeks. Improvements in ocular symptoms were observed with all study treatments.

意义重大:与非干眼症患者相比,干眼症患者的角膜上皮表面极不规则。目的:本研究旨在比较有干眼症状的人群在使用两种市售润滑眼药水和生理盐水治疗前和治疗后 4 周内角膜上皮厚度不规则因子(EIF)和眼部症状的变化:我们进行了一项前瞻性的单中心、研究者掩蔽、随机、平行组配药研究。我们招募了具有中度至重度干眼症状的参与者(基线时眼表疾病指数评分大于 23 分),并将他们随机分配到 0.15% 透明质酸 + 羟丙基瓜尔胶、0.2% 透明质酸或生理盐水组(每组 16 人)。在基线和 48 小时后、2 周后和 4 周后,沿垂直和水平 CASIA SS-1000 光学相干断层扫描测量角膜上皮厚度。在基线、2周和4周时进行了眼表疾病指数问卷调查:结果:48 名参与者(男女比例为 17:31)完成了研究。在所有随访中,水平 EIF 与基线相比均明显降低(p=0.001),但不同研究滴眼液之间无明显差异(p=0.34)。随着时间的推移(p=0.32),或不同眼药水之间(p=0.08),垂直 EIF 没有明显差异。治疗 2 周和 4 周后,眼部症状与基线相比有明显改善(p 结论:所有治疗方法都能有效减少 EIF:在开始治疗 48 小时后,所有治疗方法都能有效减少沿水平经线的 EIF,且改善效果可维持 4 周。所有治疗方法都能改善眼部症状。
{"title":"Changes in corneal epithelial irregularity following treatment with artificial tears.","authors":"Jacqueline Tan, Ngozi Chidi-Egboka, Tianni Jia, Jared Showyin, Fiona Stapleton","doi":"10.1097/OPX.0000000000002136","DOIUrl":"10.1097/OPX.0000000000002136","url":null,"abstract":"<p><strong>Significance: </strong>Dry eye sufferers have a highly irregular corneal epithelial surface compared with those without dry eye. This study demonstrated that corneal epithelial thickness irregularity can be significantly reduced after as little as 48 hours following treatment with regular use of topical ocular lubricants.</p><p><strong>Purpose: </strong>This study aimed to compare changes in corneal epithelial thickness irregularity factor (EIF) and ocular symptoms in a population with symptoms of dry eye before and up to 4 weeks after treatment with two commercially available lubricating eye drops versus saline.</p><p><strong>Methods: </strong>We conducted a prospective single-center, investigator-masked, randomized, parallel-group dispensing study. Participants with moderate to severe symptoms of dry eye (Ocular Surface Disease Index score >23 at baseline) were enrolled and randomly assigned to receive either 0.15% hyaluronic acid + hydroxypropyl guar, 0.2% hyaluronic acid, or saline (16 in each group). Corneal epithelial thickness measurements were obtained along vertical and horizontal CASIA SS-1000 Optical Coherence Tomography scans at baseline and after 48 hours, 2 weeks, and 4 weeks. The Ocular Surface Disease Index questionnaire was administered at baseline, 2 weeks, and 4 weeks.</p><p><strong>Results: </strong>Forty-eight participants (male-to-female ratio, 17:31) completed the study. Horizontal EIF was significantly lower at all follow-up visits compared with baseline (p=0.001), but there were no significant differences between study eye drops (p=0.34). No significant difference in vertical EIF was observed over time (p=0.32) or between eye drops (p=0.08). Ocular symptoms significantly improved after 2 and 4 weeks of treatment compared with baseline (p<0.001), but no differences were observed between eye drops (p=0.46).</p><p><strong>Conclusions: </strong>All treatments were effective for reducing EIF along the horizontal meridian 48 hours after initiation of treatment, and improvements were maintained for 4 weeks. Improvements in ocular symptoms were observed with all study treatments.</p>","PeriodicalId":19649,"journal":{"name":"Optometry and Vision Science","volume":" ","pages":"608-613"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141076558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing the methodology for the assessment of bulbar conjunctival lissamine green staining. 优化球结膜利萨明绿染色的评估方法。
IF 1.6 4区 医学 Q3 OPHTHALMOLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-26 DOI: 10.1097/OPX.0000000000002173
Neema Ghorbani-Mojarrad, Marta Vianya-Estopa, Eilidh Martin, Laura E Sweeney, Louise Terry, Byki Huntjens, James S Wolffsohn

Significance: When using lissamine green for bulbar conjunctival evaluation, the most staining was observed with two applications of the same strip in the same eye, wetted with a drop of saline. The first application was 5 seconds after wetting the strip, and the second was 1 minute later, followed by immediate viewing. This suggests that bulbar staining should be viewed before the lid wiper region.

Purpose: This study aimed to optimize the assessment of lissamine green staining of the bulbar conjunctiva by investigating the application technique and subsequent observation period.

Methods: Twenty-two participants with dry eye (as defined by the Tear Film and Ocular Surface Society Dry Eye Workshop II) were recruited to trial five application methods in randomized order: (1) application immediately after wetting a single strip, (2) application 5 seconds after wetting a single strip, (3) application 10 seconds after wetting a single strip, (4) consecutive single application of sodium fluorescein followed by lissamine green 5 seconds after wetting, and (5) two applications using the same lissamine green strip 5 seconds after wetting, 1 minute apart. Slit-lamp photography of the conjunctiva was performed immediately following application and at 30, 60, 90, and 300 seconds after application. Three experienced (masked) practitioners independently quantified the visible punctate spots and graded the staining intensity within the images in a random order.

Results: Values for punctate spot count ( F = 6.29, p<0.0001) and lissamine green staining intensity ( F = 6.29, p<0.0001) varied significantly between the different application methods. Using two applications of the same lissamine green strip, 1 minute apart, in the same eye resulted in the greatest values for both punctate spot count and lissamine green staining intensity. Lissamine green staining decreased with time for both spot count ( F = 18.87, p<0.0001) and lissamine green staining intensity ( F = 11.33, p<0.0001), with the most staining found immediately after application followed by a gradual decline. There was no evidence of any interaction effect between time and application method for either measure (p>0.05 for both).

Conclusions: The optimal approach for assessing bulbar conjunctival lissamine green staining involves two applications of a whole infused drop resting on the same strip for 5 seconds, applied 1 minute apart. The ocular surface should be viewed immediately after application to maximize the conjunctival staining observed.

意义重大:在使用利萨明绿进行球结膜评估时,在同一只眼睛中滴入一滴生理盐水并使用两次相同的条带可观察到最多的染色。第一次涂抹是在润湿条带后 5 秒钟,第二次是在 1 分钟后,然后立即观察。目的:本研究旨在通过研究涂抹技术和随后的观察时间,优化对球结膜利萨明绿染色的评估:招募了 22 名干眼症患者(根据泪膜与眼表学会干眼症研讨会 II 的定义),按随机顺序试用五种涂抹方法:(1) 润湿单条后立即涂抹;(2) 润湿单条后 5 秒涂抹;(3) 润湿单条后 10 秒涂抹;(4) 润湿 5 秒后连续涂抹荧光素钠和利萨明绿;(5) 润湿 5 秒后使用同一条利萨明绿涂抹两次,每次间隔 1 分钟。涂抹后立即对结膜进行裂隙灯摄影,并在涂抹后 30、60、90 和 300 秒进行摄影。三位经验丰富(蒙面)的医师独立量化可见的点状斑点,并以随机顺序对图像内的染色强度进行分级:点状斑点计数值(F = 6.29,两者的 P0.05):评估球结膜利萨明绿染色的最佳方法是在同一条带上滴入两滴完整的利萨明绿染色液,每次滴入 5 秒钟,间隔 1 分钟。滴眼后应立即观察眼球表面,以最大限度地观察结膜染色。
{"title":"Optimizing the methodology for the assessment of bulbar conjunctival lissamine green staining.","authors":"Neema Ghorbani-Mojarrad, Marta Vianya-Estopa, Eilidh Martin, Laura E Sweeney, Louise Terry, Byki Huntjens, James S Wolffsohn","doi":"10.1097/OPX.0000000000002173","DOIUrl":"10.1097/OPX.0000000000002173","url":null,"abstract":"<p><strong>Significance: </strong>When using lissamine green for bulbar conjunctival evaluation, the most staining was observed with two applications of the same strip in the same eye, wetted with a drop of saline. The first application was 5 seconds after wetting the strip, and the second was 1 minute later, followed by immediate viewing. This suggests that bulbar staining should be viewed before the lid wiper region.</p><p><strong>Purpose: </strong>This study aimed to optimize the assessment of lissamine green staining of the bulbar conjunctiva by investigating the application technique and subsequent observation period.</p><p><strong>Methods: </strong>Twenty-two participants with dry eye (as defined by the Tear Film and Ocular Surface Society Dry Eye Workshop II) were recruited to trial five application methods in randomized order: (1) application immediately after wetting a single strip, (2) application 5 seconds after wetting a single strip, (3) application 10 seconds after wetting a single strip, (4) consecutive single application of sodium fluorescein followed by lissamine green 5 seconds after wetting, and (5) two applications using the same lissamine green strip 5 seconds after wetting, 1 minute apart. Slit-lamp photography of the conjunctiva was performed immediately following application and at 30, 60, 90, and 300 seconds after application. Three experienced (masked) practitioners independently quantified the visible punctate spots and graded the staining intensity within the images in a random order.</p><p><strong>Results: </strong>Values for punctate spot count ( F = 6.29, p<0.0001) and lissamine green staining intensity ( F = 6.29, p<0.0001) varied significantly between the different application methods. Using two applications of the same lissamine green strip, 1 minute apart, in the same eye resulted in the greatest values for both punctate spot count and lissamine green staining intensity. Lissamine green staining decreased with time for both spot count ( F = 18.87, p<0.0001) and lissamine green staining intensity ( F = 11.33, p<0.0001), with the most staining found immediately after application followed by a gradual decline. There was no evidence of any interaction effect between time and application method for either measure (p>0.05 for both).</p><p><strong>Conclusions: </strong>The optimal approach for assessing bulbar conjunctival lissamine green staining involves two applications of a whole infused drop resting on the same strip for 5 seconds, applied 1 minute apart. The ocular surface should be viewed immediately after application to maximize the conjunctival staining observed.</p>","PeriodicalId":19649,"journal":{"name":"Optometry and Vision Science","volume":" ","pages":"589-594"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in Ocular Surface Research Feature Issue. 眼表研究进展》特刊。
IF 1.6 4区 医学 Q3 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1097/OPX.0000000000002188
Jennifer P Craig, James S Wolffsohn
{"title":"Advances in Ocular Surface Research Feature Issue.","authors":"Jennifer P Craig, James S Wolffsohn","doi":"10.1097/OPX.0000000000002188","DOIUrl":"10.1097/OPX.0000000000002188","url":null,"abstract":"","PeriodicalId":19649,"journal":{"name":"Optometry and Vision Science","volume":"101 9","pages":"531-534"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Silicone hydrogel versus hydrogel soft contact lenses for differences in patient-reported eye comfort and safety: A Cochrane systematic review summary. 硅水凝胶与水凝胶软性隐形眼镜在患者报告的眼睛舒适度和安全性方面的差异:Cochrane 系统综述摘要。
IF 1.6 4区 医学 Q3 OPHTHALMOLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/OPX.0000000000002161
Darian Travis, Kristina Haworth, Louis Leslie, Daniel Fuller, Andrew D Pucker

Significance: This work is significant because it is the first Cochrane systemic review that compares the comfort and safety of hydrogel and silicone hydrogel soft contact lenses (SCL).

Purpose: This study aimed to conduct a systemic review of randomized trials comparing the comfort and safety of silicone hydrogel and hydrogel SCLs.

Methods: CENTRAL, MEDLINE Ovid, EMBASE.com , PubMed, LILACS, ClinicalTrials.gov , and World Health Organization International Clinical Trials Registry Platform were searched on or before June 24, 2022, to identify randomized clinical trials that compared silicone hydrogel and hydrogel SCLs.

Results: Seven trials were identified and evaluated. One trial reported Ocular Surface Disease Index results, with the evidence being very uncertain about the effects of SCL material on Ocular Surface Disease Index scores (mean difference, -1.20; 95% confidence interval, -10.49 to 8.09). Three trials reported visual analog scale comfort score results, with no clear difference in comfort between materials, although results were of low certainty; trial results could not be combined because the three trials reported results at different time points. None of the included trials reported Contact Lens Dry Eye Questionnaire 8 or Standard Patient Evaluation of Eye Dryness scores. There was no evidence of a clinically meaningful difference (>0.5 unit) between daily disposable silicone hydrogel and hydrogel SCLs in corneal staining, conjunctival staining, or conjunctival redness (very low certainty evidence).

Conclusions: The overall evidence for a difference between all included silicone hydrogel and hydrogel SCL trials was of very low certainty, with most trials judged as having a high overall risk of bias. There was insufficient evidence to support recommending one SCL material over the other. Future well-designed trials are needed to generate high certainty evidence to further clarify differences in SCL material comfort and safety.

意义:目的:本研究旨在对比较硅水凝胶和水凝胶软性隐形眼镜(SCL)舒适性和安全性的随机试验进行系统综述:方法:检索 2022 年 6 月 24 日或之前的 CENTRAL、MEDLINE Ovid、EMBASE.com、PubMed、LILACS、ClinicalTrials.gov 和世界卫生组织国际临床试验注册平台,以确定比较硅水凝胶和水凝胶 SCL 的随机临床试验:结果:确定并评估了七项试验。其中一项试验报告了眼表疾病指数结果,证据显示SCL材料对眼表疾病指数评分的影响非常不确定(平均差异为-1.20;95%置信区间为-10.49至8.09)。三项试验报告了视觉模拟量表舒适度评分结果,不同材料的舒适度无明显差异,但结果的确定性较低;由于三项试验报告的时间点不同,因此无法合并试验结果。所纳入的试验均未报告隐形眼镜干眼症问卷 8 或眼干标准患者评估评分。没有证据表明日抛型硅水凝胶和水凝胶SCL在角膜染色、结膜染色或结膜发红方面存在有临床意义的差异(>0.5个单位):所有纳入的硅水凝胶和水凝胶SCL试验之间存在差异的总体证据确定性很低,大多数试验被判定为总体偏倚风险较高。没有足够的证据支持推荐一种SCL材料而非另一种。未来需要设计良好的试验来产生高确定性的证据,以进一步明确SCL材料在舒适性和安全性方面的差异。
{"title":"Silicone hydrogel versus hydrogel soft contact lenses for differences in patient-reported eye comfort and safety: A Cochrane systematic review summary.","authors":"Darian Travis, Kristina Haworth, Louis Leslie, Daniel Fuller, Andrew D Pucker","doi":"10.1097/OPX.0000000000002161","DOIUrl":"10.1097/OPX.0000000000002161","url":null,"abstract":"<p><strong>Significance: </strong>This work is significant because it is the first Cochrane systemic review that compares the comfort and safety of hydrogel and silicone hydrogel soft contact lenses (SCL).</p><p><strong>Purpose: </strong>This study aimed to conduct a systemic review of randomized trials comparing the comfort and safety of silicone hydrogel and hydrogel SCLs.</p><p><strong>Methods: </strong>CENTRAL, MEDLINE Ovid, EMBASE.com , PubMed, LILACS, ClinicalTrials.gov , and World Health Organization International Clinical Trials Registry Platform were searched on or before June 24, 2022, to identify randomized clinical trials that compared silicone hydrogel and hydrogel SCLs.</p><p><strong>Results: </strong>Seven trials were identified and evaluated. One trial reported Ocular Surface Disease Index results, with the evidence being very uncertain about the effects of SCL material on Ocular Surface Disease Index scores (mean difference, -1.20; 95% confidence interval, -10.49 to 8.09). Three trials reported visual analog scale comfort score results, with no clear difference in comfort between materials, although results were of low certainty; trial results could not be combined because the three trials reported results at different time points. None of the included trials reported Contact Lens Dry Eye Questionnaire 8 or Standard Patient Evaluation of Eye Dryness scores. There was no evidence of a clinically meaningful difference (>0.5 unit) between daily disposable silicone hydrogel and hydrogel SCLs in corneal staining, conjunctival staining, or conjunctival redness (very low certainty evidence).</p><p><strong>Conclusions: </strong>The overall evidence for a difference between all included silicone hydrogel and hydrogel SCL trials was of very low certainty, with most trials judged as having a high overall risk of bias. There was insufficient evidence to support recommending one SCL material over the other. Future well-designed trials are needed to generate high certainty evidence to further clarify differences in SCL material comfort and safety.</p>","PeriodicalId":19649,"journal":{"name":"Optometry and Vision Science","volume":" ","pages":"547-555"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141627243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feature issue editors. 专题编辑。
IF 1.6 4区 医学 Q3 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1097/OPX.0000000000002185
David B Elliott
{"title":"Feature issue editors.","authors":"David B Elliott","doi":"10.1097/OPX.0000000000002185","DOIUrl":"https://doi.org/10.1097/OPX.0000000000002185","url":null,"abstract":"","PeriodicalId":19649,"journal":{"name":"Optometry and Vision Science","volume":"101 9","pages":"535-536"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142896644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scoping review: Reporting characteristics for the safety of contact lenses in the pediatric population. 范围审查:儿科人群隐形眼镜安全性的报告特征。
IF 1.6 4区 医学 Q3 OPHTHALMOLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/OPX.0000000000002156
Erin S Tomiyama, Emmanuel Kobia-Acquah, Shora M Ansari, Anna-Kaye Logan, John Gialousakis, Sueko Ng, Heidi Wagner

Significance: Contact lenses are an increasingly popular option for correcting pediatric refractive error due to increased awareness of interventions to slow myopia progression. With limited information on the safety profiles of contact lenses in children, it is important to characterize the current understanding and promote this device's safe and effective use.

Purpose: This scoping review evaluates characteristics of the current literature that have examined the safety of contact lenses in pediatric patients. It provides future directions for systematic reviews and identifies any gaps in the current literature or areas for future research.

Methods: Literature searches in MEDLINE via PubMed, EMBASE, The Cochrane Library, trial registries, and U.S. Food and Drug Administration clinical trial documentation were performed. Included studies (i.e., experimental and quasi-experimental studies; observational studies including prospective and retrospective cohort, case-control, and analytical cross-sectional studies, and case series of 30 or more participants) reported safety and/or complications of the use of any contact lens for correcting refractive error in children (0 to 18 years). Two independent reviewers first screened the titles and abstracts, and then full-text reports for eligibility. Conflicts in eligibility were resolved by discussions with a third reviewer. Two independent reviewers extracted data, including details about the participants, context, study methods, and key findings relevant to the review question.

Results: This scoping review included 73 studies from 10 countries using different contact lens modalities, primarily orthokeratology and soft contact lenses, in children (6 to 18 years). The most common adverse event reported by the studies was corneal staining (60% orthokeratology, 45% soft contact lens).

Conclusions: The need for uniform reporting standards for adverse events poses challenges for comprehensive data synthesis. However, this scoping review identified a sufficient number of studies for a future systematic review to quantify the risks associated with orthokeratology and soft contact lens use in children.

意义重大:由于人们对减缓近视发展的干预措施的认识不断提高,隐形眼镜在矫正儿童屈光不正方面越来越受欢迎。由于有关儿童隐形眼镜安全性的信息有限,因此了解当前的认识并促进该设备的安全有效使用非常重要。目的:本范围综述评估了当前研究儿童隐形眼镜安全性的文献特点。它为系统性综述提供了未来的方向,并确定了当前文献中的空白或未来研究的领域:方法:通过 PubMed、EMBASE、Cochrane 图书馆、试验登记处和美国食品药品管理局临床试验文件对 MEDLINE 进行文献检索。纳入的研究(即实验和准实验研究;观察性研究,包括前瞻性和回顾性队列研究、病例对照研究和分析性横断面研究,以及 30 名或以上参与者的病例系列研究)报告了使用任何隐形眼镜矫正儿童(0 至 18 岁)屈光不正的安全性和/或并发症。两位独立审稿人首先筛选了标题和摘要,然后对报告全文进行了资格审查。与第三位审稿人的讨论解决了资格方面的冲突。两名独立审稿人提取数据,包括参与者、背景、研究方法以及与综述问题相关的主要结论等详细信息:本次范围界定综述包括来自 10 个国家的 73 项研究,这些研究采用了不同的隐形眼镜模式,主要是针对 6 至 18 岁儿童的角膜塑形镜和软性隐形眼镜。研究报告中最常见的不良事件是角膜染色(角膜矫形术占 60%,软性隐形眼镜占 45%):结论:不良事件需要统一的报告标准,这给全面的数据综合带来了挑战。然而,此次范围界定审查为未来的系统审查确定了足够数量的研究,以量化儿童使用角膜矫形术和软性隐形眼镜的相关风险。
{"title":"Scoping review: Reporting characteristics for the safety of contact lenses in the pediatric population.","authors":"Erin S Tomiyama, Emmanuel Kobia-Acquah, Shora M Ansari, Anna-Kaye Logan, John Gialousakis, Sueko Ng, Heidi Wagner","doi":"10.1097/OPX.0000000000002156","DOIUrl":"10.1097/OPX.0000000000002156","url":null,"abstract":"<p><strong>Significance: </strong>Contact lenses are an increasingly popular option for correcting pediatric refractive error due to increased awareness of interventions to slow myopia progression. With limited information on the safety profiles of contact lenses in children, it is important to characterize the current understanding and promote this device's safe and effective use.</p><p><strong>Purpose: </strong>This scoping review evaluates characteristics of the current literature that have examined the safety of contact lenses in pediatric patients. It provides future directions for systematic reviews and identifies any gaps in the current literature or areas for future research.</p><p><strong>Methods: </strong>Literature searches in MEDLINE via PubMed, EMBASE, The Cochrane Library, trial registries, and U.S. Food and Drug Administration clinical trial documentation were performed. Included studies (i.e., experimental and quasi-experimental studies; observational studies including prospective and retrospective cohort, case-control, and analytical cross-sectional studies, and case series of 30 or more participants) reported safety and/or complications of the use of any contact lens for correcting refractive error in children (0 to 18 years). Two independent reviewers first screened the titles and abstracts, and then full-text reports for eligibility. Conflicts in eligibility were resolved by discussions with a third reviewer. Two independent reviewers extracted data, including details about the participants, context, study methods, and key findings relevant to the review question.</p><p><strong>Results: </strong>This scoping review included 73 studies from 10 countries using different contact lens modalities, primarily orthokeratology and soft contact lenses, in children (6 to 18 years). The most common adverse event reported by the studies was corneal staining (60% orthokeratology, 45% soft contact lens).</p><p><strong>Conclusions: </strong>The need for uniform reporting standards for adverse events poses challenges for comprehensive data synthesis. However, this scoping review identified a sufficient number of studies for a future systematic review to quantify the risks associated with orthokeratology and soft contact lens use in children.</p>","PeriodicalId":19649,"journal":{"name":"Optometry and Vision Science","volume":" ","pages":"556-562"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Body mass index, diet, and outdoor activity linked with meibomian gland abnormalities in children. 体重指数、饮食和户外活动与儿童睑板腺异常有关。
IF 1.6 4区 医学 Q3 OPHTHALMOLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/OPX.0000000000002155
Manisha Parikh, Lindsay A Sicks, Yi Pang

Significance: Dry eye disease is frequently underdiagnosed in pediatric patients. Meibomian gland morphology abnormalities (atrophy and tortuosity) may be associated with dry eye. This study examined risk factors for gland morphology abnormalities in children.

Purpose: This study aimed to characterize meibomian gland morphological abnormalities (atrophy and tortuosity) and identify risk factors for the same in children.

Methods: A total of 160 children, primarily African American and Hispanic, aged 5 to <18 years underwent a comprehensive eye exam including slit-lamp examination to evaluate the meibomian glands, conjunctival papillae, and tear film. Infrared photography was performed including assessment of noninvasive tear film breakup time and tear meniscus height. Meibomian gland atrophy and tortuosity were assessed. A modified Ocular Surface Disease Index survey was administered along with surveys on screen time, diet, and outdoor activity. Linear multiple regression was performed to determine risk factors for meibomian gland abnormalities.

Results: The average age of participants (76 male, 84 female) was 10.9 ± 3.0 years. Severe meibomian gland atrophy (score ≥2) was found in 31.0% of participants in at least one eyelid. Severe meibomian gland tortuosity (score ≥2) was found in 84.0% of participants in at least one eyelid. The median symptom score was 9.8 (range, 0 to 71), with 16.9, 8.8, and 12.5% of the children having mild, moderate, and severe dry eye symptoms, respectively. Elevated body mass index (p<0.001), reduced outdoor activity (p=0.02), and unhealthy diet (p=0.01) were found to be risk factors for meibomian gland abnormalities. Screen time, symptom score, age, gender, and race/ethnicity were not associated with gland abnormalities (all p values >0.05).

Conclusions: This study determined that meibomian gland morphological abnormalities were commonly found in children aged 5 to <18 years. Risk factors for these abnormalities include elevated body mass index, an unhealthy diet, and reduced outdoor activity.

意义重大:干眼症在儿童患者中常常诊断不足。睑板腺形态异常(萎缩和迂曲)可能与干眼症有关。本研究探讨了儿童睑板腺形态异常的风险因素。目的:本研究旨在描述儿童睑板腺形态异常(萎缩和迂曲)的特征,并确定其风险因素:共有 160 名儿童参加了研究,主要是非裔美国人和西班牙裔美国人,年龄从 5 岁到 15 岁不等:参与者(76 名男性,84 名女性)的平均年龄为 10.9 ± 3.0 岁。31.0%的参与者至少有一个眼睑发现严重的睑板腺萎缩(评分≥2)。84.0%的参与者至少有一个眼睑发现严重的睑板腺迂曲(评分≥2)。症状评分中位数为 9.8 分(范围为 0 至 71 分),分别有 16.9%、8.8% 和 12.5%的儿童有轻度、中度和重度干眼症状。体重指数升高(P0.05):本研究发现,睑板腺形态异常常见于 5 至 6 岁的儿童。
{"title":"Body mass index, diet, and outdoor activity linked with meibomian gland abnormalities in children.","authors":"Manisha Parikh, Lindsay A Sicks, Yi Pang","doi":"10.1097/OPX.0000000000002155","DOIUrl":"10.1097/OPX.0000000000002155","url":null,"abstract":"<p><strong>Significance: </strong>Dry eye disease is frequently underdiagnosed in pediatric patients. Meibomian gland morphology abnormalities (atrophy and tortuosity) may be associated with dry eye. This study examined risk factors for gland morphology abnormalities in children.</p><p><strong>Purpose: </strong>This study aimed to characterize meibomian gland morphological abnormalities (atrophy and tortuosity) and identify risk factors for the same in children.</p><p><strong>Methods: </strong>A total of 160 children, primarily African American and Hispanic, aged 5 to <18 years underwent a comprehensive eye exam including slit-lamp examination to evaluate the meibomian glands, conjunctival papillae, and tear film. Infrared photography was performed including assessment of noninvasive tear film breakup time and tear meniscus height. Meibomian gland atrophy and tortuosity were assessed. A modified Ocular Surface Disease Index survey was administered along with surveys on screen time, diet, and outdoor activity. Linear multiple regression was performed to determine risk factors for meibomian gland abnormalities.</p><p><strong>Results: </strong>The average age of participants (76 male, 84 female) was 10.9 ± 3.0 years. Severe meibomian gland atrophy (score ≥2) was found in 31.0% of participants in at least one eyelid. Severe meibomian gland tortuosity (score ≥2) was found in 84.0% of participants in at least one eyelid. The median symptom score was 9.8 (range, 0 to 71), with 16.9, 8.8, and 12.5% of the children having mild, moderate, and severe dry eye symptoms, respectively. Elevated body mass index (p<0.001), reduced outdoor activity (p=0.02), and unhealthy diet (p=0.01) were found to be risk factors for meibomian gland abnormalities. Screen time, symptom score, age, gender, and race/ethnicity were not associated with gland abnormalities (all p values >0.05).</p><p><strong>Conclusions: </strong>This study determined that meibomian gland morphological abnormalities were commonly found in children aged 5 to <18 years. Risk factors for these abnormalities include elevated body mass index, an unhealthy diet, and reduced outdoor activity.</p>","PeriodicalId":19649,"journal":{"name":"Optometry and Vision Science","volume":" ","pages":"542-546"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feature issue editors. 特刊编辑。
IF 1.6 4区 医学 Q3 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1097/OPX.0000000000002185
David B Elliott
{"title":"Feature issue editors.","authors":"David B Elliott","doi":"10.1097/OPX.0000000000002185","DOIUrl":"https://doi.org/10.1097/OPX.0000000000002185","url":null,"abstract":"","PeriodicalId":19649,"journal":{"name":"Optometry and Vision Science","volume":"101 9","pages":"535-536"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Optometry and Vision Science
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1